Pawel Sobczuk, Postdoctoral Fellow at Vall d’Hebron Institute of Oncology (VHIO), shared a post on LinkedIn:
“For the last few years, March has always been associated with the ESMO Sarcoma and Rare Cancers Congress in Lugano. This year was no different, but for the first time, I had the pleasure of giving a talk there on ‘Strategic combinations: Rational design of immuno-sarcoma synergy’ alongside leading experts in the field, Sandra D’Angelo and Italiano Antoine.
All ESMO – European Society for Medical Oncology members can watch the recording on the OncologyPro platform. Here I will share just a few of my take-home messages:
- We still don’t have clear biological evidence how to best combine immunotherapeutic agents with systemic therapy or radiotherapy in sarcoma
- Different fractionation of radiotherapy may have different immunomodulatory effects, while hypofractionated regimens seem to have more biological rationale
- We lack data for hypofractionated radiotherapy in combination with IO in sarcoma
- TME modulation by radiotherapy or systemic agents may vary depending on sarcoma subtype
- Most of the clinical trials with IO+systemic agents in sarcoma have failed
- We could use the ‘window-of-opportunity’ approach before surgery in localized disease to study activity of combinations with biological endpoints (pathological response, etc.)
I am happy to discuss your thoughts on this topic and what we can do more as the sarcoma community to move the field forward.
Additionally, I had the pleasure of participating in a Workshop for Patient Advocates to discuss how we can make clinical trials for rare tumors more inclusive and patient-centered. Finally, despite already retiring from Young Oncologists Committee, I was happy to support and chair YO sessions together with fantastic Paula Isabel Franco!
Looking forward to coming back to Lugano in 2027.”
Other Articles Featuring Pawel Sobczuk on OncoDaily.
